KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Short term Debt (2016 - 2023)

West Pharmaceutical Services' Short term Debt history spans 15 years, with the latest figure at $2.2 million for Q3 2023.

  • For Q3 2023, Short term Debt changed 0.0% year-over-year to $2.2 million; the TTM value through Sep 2023 reached $2.2 million, changed 0.0%, while the annual FY2021 figure was $44.2 million, 1821.74% up from the prior year.
  • Short term Debt for Q3 2023 was $2.2 million at West Pharmaceutical Services, roughly flat from $2.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $44.2 million in Q3 2021 and bottomed at $2.2 million in Q1 2022.
  • The 5-year median for Short term Debt is $2.3 million (2019), against an average of $7.8 million.
  • The largest annual shift saw Short term Debt surged 2200.0% in 2019 before it crashed 95.02% in 2022.
  • A 5-year view of Short term Debt shows it stood at $2.3 million in 2019, then changed by 0.0% to $2.3 million in 2020, then skyrocketed by 1821.74% to $44.2 million in 2021, then plummeted by 95.02% to $2.2 million in 2022, then changed by 0.0% to $2.2 million in 2023.
  • Per Business Quant, the three most recent readings for WST's Short term Debt are $2.2 million (Q3 2023), $2.2 million (Q2 2023), and $2.2 million (Q1 2023).